Prostate News Archive
03-May-2009
Large, Long-term Study Shows Dutasteride Reduced Prostate Cancer Risk In Men At Increased Risk Of The Disease (Medical News Today)
Headline data from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial was presented at the American Urological Association in Chicago, Illinois today. The study population was men between the ages of 50 and 75 who were at increased risk for prostate cancer with prostate specific antigen (PSA) levels between 2.5 and 10 ng/mL (men aged 50 to 60 years) and between 3.0 and 10. Yale president has surgery for prostate cancer (Boston Globe)
Yale president Richard Levin is recovering after what school officials say was successful surgery for prostate cancer. Agent Orange worsens prostate cancer prognosis (Reuters via Yahoo! News)
Among Vietnam veterans who have undergone major prostate cancer surgery, those who were exposed to Agent Orange have an increased risk of an aggressive recurrence, according to results of a study appearing in the British Journal of Urology (BJU) International. US FDA approves OncoGenex's 2nd phase-3 trial design of OGX-011 to treat castrate resistant prostate cancer (PharmaBiz)
OncoGenex Pharmaceuticals, Inc has reached an agreement with the US Food and Drug Administration (FDA) on the design of a second phase-3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the Special Protocol Assessment (SPA) process. Gen-Probe, Diagnocure Amend Prostate Cancer Test Deal (GenomeWeb News)
NEW YORK (GenomeWeb News) ? Gen-Probe and DiagnoCure said this week that they have amended their 2003 license agreement regarding development and commercialization of a molecular diagnostic test for prostate cancer.
Back to Prostate News Archive
